{
    "clinical_study": {
        "@rank": "117719", 
        "acronym": "DESIRABLE", 
        "arm_group": [
            {
                "arm_group_label": "Denosumab 6 months", 
                "arm_group_type": "Experimental", 
                "description": "denosumab administered subcutaneously every 6 months"
            }, 
            {
                "arm_group_label": "Denosumab 3 months", 
                "arm_group_type": "Experimental", 
                "description": "denosumab administered subcutaneously every 3 months"
            }, 
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "placebo administered subcutaneously to match denosumab"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate the inhibitory effect of progression, compared with placebo, in joint\n      destruction by AMG 162 administered subcutaneously to rheumatoid arthritis patients"
        }, 
        "brief_title": "AMG 162 (Denosumab) Phase 3 Study (DESIRABLE Study) in Patients With Rheumatoid Arthritis on Disease-modifying Antirheumatic Drugs (DMARDs) Treatment", 
        "completion_date": {
            "#text": "March 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "detailed_description": {
            "textblock": "To evaluate the inhibitory effect of progression, compared with placebo, in joint\n      destruction by AMG 162 administered subcutaneously at a dose of 60 mg every 6 months or\n      every 3 months for 12 months to rheumatoid arthritis patients"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosed with rheumatoid arthritis according to the American College of Rheumatology\n             (ACR) criteria for rheumatoid arthritis classification (1987 revision) or the 2010\n             ACR-EULAR (The European League Against Rheumatism) classification criteria for\n             rheumatoid arthritis\n\n        Exclusion Criteria:\n\n          -  Functional class IV according by the ACR revised classification (1991)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "642", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01973569", 
            "org_study_id": "AMG162-D-J301"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Denosumab 6 months", 
                    "Denosumab 3 months"
                ], 
                "description": "denosumab administered subcutaneously", 
                "intervention_name": "denosumab", 
                "intervention_type": "Drug", 
                "other_name": "AMG 162"
            }, 
            {
                "arm_group_label": "placebo", 
                "description": "placebo administered subcutaneously to match denosumab", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Antirheumatic Agents"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Rheumatoid Arthritis", 
            "Denosumab", 
            "RANKL", 
            "RANK", 
            "AMG 162", 
            "joint damage"
        ], 
        "lastchanged_date": "December 2, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Tokyo", 
                    "country": "Japan", 
                    "zip": "162-0054"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Confirmatory Study of AMG 162 (Denosumab) in Patients With Rheumatoid Arthritis on DMARDs Treatment (Phase III)", 
        "overall_contact": {
            "email": "nitta.takaya.w6@daiichisankyo.co.jp", 
            "last_name": "Takaya Nitta", 
            "phone": "03-5740-3782"
        }, 
        "overall_official": {
            "affiliation": "Division of Rheumatology Department of Internal Medicine, Keio University", 
            "last_name": "Tsutomu Takeuchi, Prof.", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Change from baseline in Total Sharp Score (TSS) from baseline to month 12.", 
            "measure": "Change from baseline in Total Sharp Score (TSS) at month 12", 
            "safety_issue": "No", 
            "time_frame": "baseline to month 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01973569"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Change from baseline in Total Sharp Score (TSS) from baseline to month 6.", 
                "measure": "change form baseline in TSS at month 6", 
                "safety_issue": "No", 
                "time_frame": "baseline to month 6"
            }, 
            {
                "description": "Change from baseline in Erosion Score from baseline to month 6.", 
                "measure": "change form baseline in Erosion Score at month 6", 
                "safety_issue": "No", 
                "time_frame": "baseline to month 6"
            }, 
            {
                "description": "Change from baseline in Joint Space Narrowing from baseline to month 6.", 
                "measure": "change form baseline in Joint Space Narrowing at month 6", 
                "safety_issue": "No", 
                "time_frame": "baseline to month 6"
            }, 
            {
                "description": "Change from baseline in Erosion Score from baseline to month 12.", 
                "measure": "change form baseline in Erosion Score at month 12", 
                "safety_issue": "No", 
                "time_frame": "baseline to month 12"
            }, 
            {
                "description": "Change from baseline in Joint Space Narrowing from baseline to month 12.", 
                "measure": "change form baseline in Joint Space Narrowing at month 12", 
                "safety_issue": "No", 
                "time_frame": "baseline to month 12"
            }, 
            {
                "description": "percent change from baseline in Bone Mineral Density (BMD) at month 12", 
                "measure": "percent change from baseline in Bone Mineral Density (BMD) at month 12", 
                "safety_issue": "No", 
                "time_frame": "baseline to month 12"
            }
        ], 
        "source": "Daiichi Sankyo Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Daiichi Sankyo Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}